COVID-19 infection is associated with a meaningful rise in new cases of type 1 diabetes, particularly in children and adolescents. A large meta-analysis found that the incidence of type 1 diabetes in young people climbed roughly 14% in the pandemic’s first year and 27% in the second year compared with pre-pandemic levels. The relationship is more tangled than a simple cause-and-effect chain, though, because the pandemic also disrupted healthcare access, delayed diagnoses, and introduced confounders that muddy the picture. Understanding what the virus itself does to insulin-producing cells, and what the pandemic’s broader disruptions contributed separately, matters for anticipating long-term consequences.
Rising Rates in Children and Adolescents
The most robust epidemiological signal comes from pediatric populations. A systematic review and meta-analysis pooling data from over 38,000 children and adolescents with newly diagnosed type 1 diabetes found a statistically significant increase in incidence during the pandemic. In the first 12 months, the incidence rate was about 14% higher than pre-pandemic baseline; in months 13 through 24, it jumped to 27% higher.1PubMed Central. Incidence of Diabetes in Children and Adolescents During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis The fact that the increase grew larger in the second year, rather than leveling off, caught researchers’ attention and argued against it being a one-time reporting artifact.
American data told a similar story. Comparing 2020–2021 with 2016–2019, type 1 diabetes incidence among youth was 17% higher overall. The increase was especially pronounced among those aged 10 to 19, male individuals, and Hispanic youth.2JAMA Network Open. Incidence of Diabetes Among Youth Before and During the COVID-19 Pandemic These demographic patterns may reflect differences in viral exposure, healthcare access, or genetic susceptibility, though the data so far cannot tease those apart cleanly.
The link extends beyond children. A separate meta-analysis looking at all age groups found that people who had been infected with SARS-CoV-2 faced roughly 60% higher relative risk of developing diabetes of any type afterward, with elevated risk present in those under 18, adults, and older adults alike.3PubMed Central. Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis A more recent systematic review estimated the overall prevalence of new-onset diabetes after COVID-19 at about 1.4%, with type 2 diabetes making up the majority of cases and type 1 accounting for a much smaller share.4PubMed Central. New onset of type 1 and type 2 diabetes post-COVID-19 infection: a systematic review So while most post-COVID diabetes is type 2, the type 1 signal is real and disproportionately affects the young.
How SARS-CoV-2 Reaches Insulin-Producing Cells
Type 1 diabetes develops when the beta cells of the pancreas, which produce insulin, are destroyed. A central question has been whether SARS-CoV-2 can directly damage those cells. The answer appears to be yes. Researchers demonstrated that the virus infects human pancreatic beta cells both in autopsy tissue from patients who died of COVID-19 and in lab-grown human islets. Once inside, the virus reduced insulin production, impaired insulin secretion, and triggered a cell-death pathway that resembles what happens in classic type 1 diabetes. Blocking a protein called NRP1, which the virus uses as a co-receptor to enter cells, rescued the beta cells from this damage.5PubMed Central. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment
The virus’s entry point into pancreatic tissue involves ACE2, the same receptor it uses to invade lung cells. Pancreatic islet cells express ACE2, and SARS-CoV-2 has been found in pancreatic tissue from COVID-19 patients, providing anatomical evidence that the virus reaches the organ during infection.6PubMed Central. ACE2 function in the pancreatic islet: Implications for relationship between SARS-CoV-2 and diabetes ACE2-mediated pancreatic injury may extend beyond the beta cells. A small case series documented exocrine pancreatic insufficiency in COVID-19 patients who developed diarrhea, suggesting broader pancreatic damage via the same receptor pathway.7PubMed Central. Diarrhea due to SARS-CoV-2-Related Exocrine Pancreatic Insufficiency
Immune Mechanisms That Could Trigger Autoimmunity
Direct viral killing of beta cells is only one piece. Type 1 diabetes is fundamentally an autoimmune disease, and several immune-mediated pathways may link COVID-19 to its onset. The most discussed is molecular mimicry: parts of the SARS-CoV-2 virus resemble proteins found on human beta cells closely enough that the immune system, revved up to fight the virus, accidentally attacks the body’s own insulin-producing cells. Computational analysis has identified sequence similarities between viral proteins and both human insulin and GAD65, a key autoantigen in type 1 diabetes, suggesting a plausible route for an immune cross-reaction.8Research Square. Triggering type 1 diabetes post-covid: molecular mimicry? This remains a theoretical framework supported by modeling data rather than direct clinical proof, but it fits a well-established pattern seen with other viruses.
Another proposed mechanism involves what researchers call bystander damage. When the virus infects pancreatic cells adjacent to the beta cells, the resulting inflammatory response spills over. The immune cells and inflammatory molecules released to fight the infection in nearby tissue end up destroying beta cells as collateral damage.9ScienceDirect. New onset diabetes, type 1 diabetes and COVID-19 A third possibility involves post-translational modifications: the virus may alter proteins on beta cells in ways that create new targets the immune system has never learned to tolerate, provoking an autoimmune response where none existed before.10Diabetes/Metabolism Research and Reviews. SARS-CoV-2 induced post-translational protein modifications: A trigger for developing autoimmune diabetes?
These pathways are not mutually exclusive. In fact, they may compound one another: the virus directly kills some beta cells, inflammatory bystander effects take out more, and molecular mimicry or altered proteins keep the immune assault going after the infection clears. This layered attack would explain why some people develop rapid-onset type 1 diabetes during acute infection while others show a slower emergence of autoimmunity months later.
Early Signs of Autoimmunity in Very Young Children
One of the more striking findings comes from a study tracking young children at genetic risk for type 1 diabetes. Among 170 children who developed SARS-CoV-2 antibodies (indicating prior infection), the rate of subsequently developing islet autoantibodies, the earliest measurable sign of type 1 diabetes’s autoimmune process, was roughly doubled compared with children who had not been infected. The adjusted hazard ratio was 3.5, meaning children with evidence of COVID-19 were about three and a half times more likely to develop islet autoantibodies.11JAMA. SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood
The risk was highest among children who were infected before 18 months of age, where the hazard ratio climbed above 5.11JAMA. SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood Islet autoantibodies do not guarantee that a child will develop type 1 diabetes, but they are the strongest known predictor. Most children who develop multiple islet autoantibodies will eventually progress to clinical diabetes, often over years. This finding raises the possibility that a wave of COVID-related type 1 diabetes in very young children may still be unfolding, with clinical diagnoses appearing years after the initial infections.
More Severe Disease at Diagnosis
The pandemic did not only bring more type 1 diabetes diagnoses. It also brought sicker patients at the point of diagnosis. Diabetic ketoacidosis, a dangerous complication that occurs when the body runs critically low on insulin and starts breaking down fat for fuel, became significantly more common and more severe among children newly diagnosed during the pandemic. A meta-analysis covering more than 124,000 children found a 41% increase in DKA risk among new type 1 diabetes cases during the pandemic, with severe DKA rising by 66%.12PubMed Central. Incidence of diabetic ketoacidosis during COVID-19 pandemic: a meta-analysis of 124,597 children with diabetes
Individual studies bore this out in stark terms. One found that the frequency of DKA at initial type 1 diabetes diagnosis jumped from about 46% before the pandemic to 68% during it, while severe DKA roughly doubled from 13% to 27%.13PubMed Central. Diabetic ketoacidosis at type 1 diabetes diagnosis in children during the COVID-19 pandemic Another confirmed that children diagnosed during the pandemic presented with more severe metabolic derangement.14PubMed Central. Severity and Resolution of Diabetic Ketoacidosis in Newly Diagnosed Type 1 Diabetic Children before and During The COVID-19 Pandemic
The severity increase was not entirely the virus’s doing. Pandemic-era lockdowns, overburdened hospitals, the shift to telemedicine, and families’ reluctance to seek care for fear of catching COVID-19 all contributed to delays in recognizing early symptoms of type 1 diabetes, which in turn allowed more children to progress to DKA before receiving a diagnosis.15PubMed Central. The impact of COVID-19 pandemic on the incidence, presentation, and management of type 1 diabetes in children and adolescents: a narrative review This is an important distinction: the virus may have been generating more type 1 diabetes, but the pandemic’s disruption of routine healthcare was independently making each case worse by the time it was caught.
Separating the Virus from the Pandemic
The biggest unresolved question in this field is how much of the increase in type 1 diabetes is caused by SARS-CoV-2 infection itself and how much reflects the pandemic’s indirect effects. Several confounders complicate the picture. Stress hyperglycemia, a temporary spike in blood sugar driven by the body’s acute illness response, can masquerade as new diabetes. Corticosteroids, which were widely used to treat severe COVID-19, also raise blood sugar. And some patients diagnosed with “new” diabetes during hospitalization may have had undiagnosed diabetes beforehand that only became apparent under medical scrutiny.16PubMed Central. COVID-19, Hyperglycemia, and New-Onset Diabetes
One study that followed patients diagnosed with diabetes at the time of COVID-19 hospitalization found that roughly half experienced regression of their diabetes afterward, suggesting that a substantial portion of new diagnoses during acute illness were temporary rather than permanent.17PubMed Central. Newly diagnosed diabetes vs. pre-existing diabetes upon admission for COVID-19: Associated factors, short-term outcomes, and long-term glycemic phenotypes This is reassuring for adult patients hospitalized with high blood sugar, but it applies mostly to type 2 patterns and stress hyperglycemia rather than to children developing autoimmune type 1 diabetes.
Perhaps the most provocative evidence against a direct viral cause came from a study examining children who were newly diagnosed with type 1 diabetes during the pandemic: only about 1% tested positive for SARS-CoV-2 antibodies, meaning the vast majority had no serological evidence of prior infection at the time of their diagnosis. A large registry analysis of nearly 52,000 children in the US and Germany also found no significant association between SARS-CoV-2 antibodies and the development of type 1 diabetes-related autoantibodies.18JAMA Network Open. Elucidating the Underlying Mechanisms of the Marked Increase in Childhood Type 1 Diabetes During the COVID-19 Pandemic—The Diabetes Pandemic This finding is difficult to reconcile with the autoimmunity data from younger, genetically at-risk children described earlier, and it has led some researchers to look beyond the virus for explanations: pandemic-era changes in children’s exposure to other infections, altered gut microbiomes due to hygiene measures, reduced physical activity, and psychological stress have all been floated as contributing factors.
The tension between these datasets is real and has not been fully resolved. It is possible that the virus is a potent trigger in genetically susceptible individuals, particularly very young children, while the broader population-level increase reflects a mixture of viral effects and pandemic disruption. The two explanations are not incompatible.
A Genetic Dimension
Type 1 diabetes has always been a disease with a strong genetic component. Certain gene variants in the HLA region, which governs immune recognition, are the strongest known risk factors. Research has explored whether some of the same genetic architecture that predisposes a person to type 1 diabetes also affects how their body responds to SARS-CoV-2. One hypothesis points to a genetic variant associated with immune-cell behavior in the lungs that contributes substantially to type 1 diabetes risk. The same variant may influence how the immune response to a respiratory virus like SARS-CoV-2 unfolds, potentially creating a bridge between severe COVID-19 and the initiation of autoimmune beta-cell destruction.19Medical Hypotheses. COVID-19 infection activates genetically predisposed risk pathways in lungs to escalate T1D development This remains speculative but offers one explanation for why COVID-19 might trigger type 1 diabetes in some people and not others: genetic background determines who is vulnerable.
COVID-19 Vaccination and Type 1 Diabetes Risk
A natural concern for parents and patients has been whether COVID-19 vaccines themselves might trigger type 1 diabetes. A large population-based study in China, drawing on registry data from over 14 million people between 2007 and 2021, found no increase in type 1 diabetes incidence during the vaccination rollout in 2021. The incidence rate remained stable from 2019 through 2021, and the rate of fulminant type 1 diabetes, a particularly rapid and severe subtype, likewise showed no increase.20PubMed Central. Association between Covid-19 vaccination and incidence of type 1 diabetes in China: Evidence from 14.14 million registered residents between 2007 and 2021 This is consistent with the broader safety profile of COVID-19 vaccines and offers substantial reassurance. The risk, to the extent it exists, appears to come from the infection, not the vaccine.
Viruses and Type 1 Diabetes Before COVID
The idea that a viral infection could trigger type 1 diabetes did not begin with SARS-CoV-2. Coxsackievirus B, a common enterovirus, has been linked to type 1 diabetes for decades. Evidence from prospective birth cohorts and pancreas tissue studies has built a compelling case that coxsackievirus can infect beta cells, provoke immune-mediated destruction, and potentially initiate autoimmunity through the same kind of molecular mimicry mechanisms now proposed for COVID-19.21PubMed. Coxsackievirus and Type 1 Diabetes: Diabetogenic Mechanisms and Implications for Prevention Rubella, mumps, and cytomegalovirus have also been investigated as possible triggers over the years.
This history matters because it shifts the framing of the COVID-type 1 diabetes connection from something unprecedented to something that fits a known pattern. Type 1 diabetes has likely always had an environmental trigger component, with viral infections playing a role in at least some cases. What makes SARS-CoV-2 different is scale: hundreds of millions of infections in a compressed time frame created a natural experiment that epidemiologists could track in near-real time. The pandemic may ultimately teach researchers more about how viruses trigger autoimmune diabetes in general than about COVID-19 specifically.
What Families and Clinicians Should Watch For
For parents, the practical takeaway is awareness rather than alarm. The absolute risk of a child developing type 1 diabetes after a COVID-19 infection remains low, even if the relative risk is elevated. But the symptoms of type 1 diabetes in children, including excessive thirst, frequent urination, unexplained weight loss, and persistent fatigue, deserve prompt medical evaluation, particularly in children who have recently had COVID-19. The pandemic demonstrated clearly that delays in recognizing these symptoms lead to more severe presentations at diagnosis, and that problem is entirely preventable with timely care.
For clinicians managing patients who developed diabetes around the time of a COVID-19 infection, the diagnostic picture can be genuinely confusing. The diabetes may be classic autoimmune type 1, type 2 driven by insulin resistance, stress-induced hyperglycemia that resolves, steroid-induced hyperglycemia that resolves, or something that does not fit neatly into existing categories.16PubMed Central. COVID-19, Hyperglycemia, and New-Onset Diabetes Testing for islet autoantibodies and C-peptide levels can help distinguish among these, but longitudinal follow-up is needed because the phenotype may evolve over months. As the earlier-cited evidence suggests, roughly half of adults diagnosed with diabetes during COVID-19 hospitalization see their blood sugar normalize afterward, but the other half do not, and the factors predicting who falls into which group remain poorly understood.